Creative Biolabs has focused on the research of antibacterial antibodies/peptides for many years. As thus, we have extensive experience in discovery of novel antibodies and peptides targeting Streptococcus. Currently, an innovative Anti-Bacteria Biomolecular Discovery platform has been developed by our skilled expert team, thus allowing us to offer the high-quality Streptococcus-specific antibodies and peptides for clients from all over the world in an efficient manner.
Streptococcus is a genus of Gram-positive coccus (plural cocci) or spherical bacteria. It contains many species, most of which are symbiotic bacteria (commensal flora) and beneficial bacteria such as S. thermophilus. But there are also a considerable number of pathogenic bacteria species. Based on hemolytic properties, Streptococcus species are classified as α-hemolytic species and β-hemolytic species. The α-hemolytic species includes S. pneumonia and S. viridans group and the β-hemolytic species contains group A S. pyogenes (GAS) and group B Streptococcus (GBS).
GBS is an important cause of neonatal morbidity and mortality, as well as maternal and non-pregnant adult infections, in spite of antibiotic and supportive therapy. Most GBS strains produce strain-variable and surface-localized proteins containing Cα and R4 proteins. Cα and R4 proteins have been found in approximately 75% of clinical GBS isolates and been considered as important serotype markers and targets of diagnostic and protective antibodies.
SIP has reported as a highly conserved protein of GBS. It induces a protective effect against lethal GBS challenge. And vaccines targeting SIP display a similar effect in mouse model, as they reduce vaginal GBS colonization and elicit specific to SIP antibodies which have opsonophagocytosis activities against GBS.
S. pneumoniae is a major infectious agent that is responsible for pneumonia, otitis media, sepsis, and meningitis. PspA is a well-characterized virulence factor localized on the surface and a target for vaccine development. Besides, a commercial PspA antibody displays a better specificity towards recombinant PspA antigen, which can be used for detecting endogenous PspA and pneumococcal diseases.
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics and can be used to defeat multidrug-resistant bacteria such as S. pneumoniae. Most AMPs have been designed and synthesized to verify their antibacterial activity against Streptococcus, such as four hybrid peptides of two natural peptides indolicidin and ranalexin (RN7-IN10, RN7-IN9, RN7-IN8, and RN7-IN6), as well as a chemically synthesized peptide M-Brucin. In Creative Biolabs, we can construct a custom peptide phage library and screen high-specific peptide targeting Streptococcus.
Creative Biolabs is a world-leading service provider for discovery of antibodies and peptides targeting Streptococcus. Based on a powerful AntInfectTM Platform which is optimal for the discovery of novel anti-bacteria agents, we are very proud of providing the best services of anti-Streptococcus biomolecular discovery for customers from all over the world. If you are interested in the discovery of Streptococcus antibodies and peptides, please feel free to contact us for more details.
